for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
  PharmAsia News
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [13 journals]
  • India Envisions Global Scale In Devices But Local Prices To Be Curbed'
    • Abstract: A task force report constituted by the Indian government proposes various efforts to grow the medical device industry locally, but some provisions on controlling pricing of mainly imported devices may need further deliberations.
      PubDate: Wed, 15 Apr 2015 07:15:02 -040
  • Lummy Strikes First Deal Under VC Fund Investment
    • Abstract: TVM Capital Life Science has established a new $50 million venture capital fund with investment from Chinese partner Lummy, which has already tapped the new vehicle for a licensing deal for an oncology dendritic vaccine.
      PubDate: Wed, 15 Apr 2015 01:20:00 -040
  • EXCLUSIVE INSIGHT: China To Clarify MRCT Regulatory Pathway Soon
    • Abstract: One year after breaking the story of China starting a review of the widely used multiregional clinical trial pathway, PharmAsia News talks to regulatory affairs insiders to unearth coming changes that will have far-reaching effects on R&D-based drug firms in the country.
      PubDate: Tue, 14 Apr 2015 21:45:04 -040
  • Chong Kun Dang links With Indonesia’s OTTO For ASEAN Expansion
    • Abstract: Looking to expand its presence in Indonesia and other Southeast Asian countries, South Korea’s Chong Kun Dang Pharmaceutical has agreed to set up a joint venture with Bandung-based Otto Pharmaceutical Industries.
      PubDate: Tue, 14 Apr 2015 19:25:01 -040
  • Tresiba Bolsters Novo Nordisk’s Japan Position
    • Abstract: Novo Nordisk’s diabetes market share in Japan is regaining ground as newer products Tresiba and Victoza carve out niches in the highly competitive sector.
      PubDate: Tue, 14 Apr 2015 05:40:00 -040
  • ANALYSIS: Will Sun-Ranbaxy Pairing Trigger More M&As In India'
    • Abstract: The Indian pharmaceutical market is seeing a decisive shift. Starting now, Sun and Ranbaxy as a combined organization will dislodge Abbott from its top position held for over five years.
      PubDate: Tue, 14 Apr 2015 02:25:00 -040
  • Eisai Cuts U.S. Jobs In ‘Realignment’
    • Abstract: Eisai is cutting a little over 200 people from its U.S. commercial and regional corporate services units in what the Japanese pharma firm is dubbing a "realignment of its US operations." The move follows weaker than expected sales for several new drugs.
      PubDate: Mon, 13 Apr 2015 21:05:01 -040
  • Korean Health Policy Blueprint Aims To Step Up Collaborations
    • Abstract: South Korea’s Ministry of Health and Welfare laid out its future policy directions for the country's healthcare industry during this year's Bio Korea international convention in Seoul.
      PubDate: Mon, 13 Apr 2015 18:35:00 -040
  • New Guidance Tackles Australian Post-Market Review Worries
    • Abstract: A new version of the Australian framework for post-market reviews, which are used to monitor marketed medicines in order to improve the quality of their use and help ensure the sustainability of the Pharmaceutical Benefits Scheme, is expected to be published soon following its adoption by the government and the pharmaceutical industry.
      PubDate: Mon, 13 Apr 2015 04:05:02 -040
  • Asian Industry Groups Progress Initiatives For Faster Approvals
    • Abstract: 12 research-based industry associations across Asia have held their fourth annual confab at which working group proposals on drug discovery alliances, regulations and approvals moved forward with the ultimate aim of speeding up the availability of innovative medicines their members produce.
      PubDate: Mon, 13 Apr 2015 01:10:00 -040
  • PROFILE: A Leaner, Faster and Cheaper China Drug Development Model
    • Abstract: Collaborating with academics to develop new drugs may not be new, but using six sigma principles to do so certainly is.
      PubDate: Sun, 12 Apr 2015 19:20:02 -040
  • Korea’s CJ Looking To P-CAB, Biosimilars To Double Revenues
    • Abstract: CJ HealthCare, the pharma affiliate of South Korea's CJ Group, is aiming to more than double its annual revenues to KRW1 trillion ($910 million) by 2020 by developing new drugs and biosimilars.
      PubDate: Fri, 10 Apr 2015 05:10:01 -040
  • Aurobindo Settles Dispute With Plethico Over Natrol Fraud Charges
    • Abstract: Last year Aurobindo acquired Plethico’s Natrol dietary supplements business in the U.S., which was divested as part of court-directed bankruptcy proceedings. A few months on, the Hyderabad-based drug maker filed a case charging the seller of perpetrating fraud.
      PubDate: Thu, 09 Apr 2015 20:40:00 -040
  • The Biosimilar Patent Dance, Exclusivity, And Unintended Innovation
    • Abstract: As brand firms are learning with biosimilars, laws can turn out in unexpected ways – but there may well be some pleasant surprises in the U.S. 21st Century Cures legislation.
      PubDate: Thu, 09 Apr 2015 19:25:01 -040
  • Pfizer Among 10 Most Profitable Pharma Firms In China
    • Abstract: Sanofi, Roche and Bayer are also ranked among the top 50 companies in profit terms despite foreign drug makers being generally smaller than their Chinese domestic counterparts.
      PubDate: Thu, 09 Apr 2015 04:05:01 -040
  • Bayer Sees Innovation As Best Japan Growth Strategy
    • Abstract: Bayer Yakuhin in Japan is aiming to grow three times faster than the overall pharma market in the country in 2015, mainly on the back of strong growth for Xarelto, Eylea and other new drugs.
      PubDate: Thu, 09 Apr 2015 02:50:02 -040
  • Korean Govt Touts M&A As Fastest Pharma Route Into China
    • Abstract: Amid the South Korean government's recent drive to encourage pharma firms to shift their focus to overseas markets, an official at the country's state-owned health industry institute has suggested the industry should seek mergers and acquisitions or joint ventures to advance into the rapidly growing Chinese pharma market.
      PubDate: Wed, 08 Apr 2015 21:55:01 -040
  • Trickle To Deluge: India To See More Sovaldi Knock-Offs'
    • Abstract: In a short time, India may see a large number of suppliers of generic sofosbuvir via sub-licensing deals with two key raw material suppliers.
      PubDate: Wed, 08 Apr 2015 19:50:03 -040
  • Lilly Aims For Japan Top 10 On New Launches
    • Abstract: Lilly remains bullish about its business in Japan on the back of strong sales increases over the past few years, and is confident it can achieve a top 10 ranking in the industry by 2020 following a slew of launches this year.
      PubDate: Wed, 08 Apr 2015 04:50:01 -040
  • Heart Breaking: India Shows Sharp Rise In CVDs
    • Abstract: The alarmingly growing number of cardiovascular complications in India is sending worrying signals as the Indian government grapples with infrastructure issues.
      PubDate: Tue, 07 Apr 2015 21:05:00 -040
  • Emerging Markets Regulatory Tracker: India Seeks Experts For New E-System
    • Abstract: India’s CDSCO is seeking IT experts to help with a proposed system of e-applications for new drugs.
      PubDate: Tue, 07 Apr 2015 20:50:27 -040
  • New Data Reveal Rising Antidepressant Use In Turkey
    • Abstract: Turkey’s minister of health has said the total number of antidepressant users in Turkey has risen to over eight million, with middle aged women the main patient group. Sales of some types of products surged by 16% last year.
      PubDate: Tue, 07 Apr 2015 20:50:00 -040
  • Looking To Grow In China’s New Norm' Think Local
    • Abstract: As China steps up regulatory enforcement more affirmatively and forcefully, multinational firms are starting to search for ways to adapt to a slowing economy and increasingly challenging environment. The need to drive growth at a local level is vital to thriving in this “new norm”, says a senior government relations executive.
      PubDate: Tue, 07 Apr 2015 19:20:45 -040
  • Despite Bubble Fears, Korean Biopharma Rally Has Room To Run
    • Abstract: A slew of promising news on new drug development and robust exports by South Korean pharma firms, coupled with a global biotech rally, have fueled appetite for the country’s pharma and biotech stocks so far this year.
      PubDate: Mon, 06 Apr 2015 19:05:00 -040
  • INTERVIEW: MNCs In Cautious ‘Second Wave’ Marketing Plans For
    • Abstract: Experts in sales and marketing say leading global drug makers are looking to professionalize their country organizations as part of their “second wave” plans in Asia. Greater use of data techniques can change the way health experts are approached and help optimize company operations.
      PubDate: Mon, 06 Apr 2015 19:00:01 -040
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015